Pressmeddelande -
Airsonett supports the Allergy Diary App – assists in the care of allergic asthma
The new app Allergy Diary has been developed for IOS and Android in collaboration between MACVIA-LR and ARIAR, a European network for monitoring allergy. The app is an important tool for the effective treatment of severe allergic asthma as it assists patients in keeping track of their symptoms. The app is simple to use, and combines practicality with good scientific practice, having been developed with a global team of world leading allergy clinicians. The app can be downloaded here (https://itunes.apple.com/fi/app/allergy-diary-by-macvia-aria/id983596216?mt=8,https://play.google.com/store/apps/details?id=nl.peercode.allergydiary&hl=en) and on Airsonett's website.
“In order for the healthcare system to be able to follow the daily changes, the importance of some form of symptom diary is great” says Therese Sterner, Leg. Allergy, Asthma and COPD nurse with skin specialization. She continues: “This can easily be done through the Allergy Diary app. Studies have shown positive results with this form of allergy diary, as it monitors symptom changes over time which assists both the user and the health care system,”.
Anders Due-Boje, CEO of Airsonett, agrees: “In all treatment it is of the utmost importance that patients can document their symptoms. We support this app to help patients easily keep track of their symptoms so the national health services can provide optimal care for each patient. "
Airsonett is a unique treatment for allergic asthma
Airsonett® Air4 is a medical device for effective home treatment of allergic asthma and eczema. The patented TLA technology provides 99.5% clean air in the breathing zone. Your airways and immune system can rest and recuperate when you sleep, and you wake up rested, ready for a new day. The technology is clinically documented for several years and now wins land in many county councils.
"As my role as an Allergy Nurse, both in the County Council and as a consultant, I monitor children and adults since 2007 with severe asthma who have an Airsonett installed. Sleeping under an Airsonett has, with a few exceptions, resulted in huge improvements for the individual patient but also for the family. Sleeping undisturbed without coughing and itching a whole night increases the possibility of a better everyday life”, says Therese Sterner, Leg. Allergy, Asthma and COPD nurse with skin specialization.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu
Ämnen
- Hälso-, sjukvård
Kategorier
- asthma treatment
- asthma
- airsonett airshower
- airsonett
- eczema
- allergic asthma
About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett®Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett®Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep.Airsonett®Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett®Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu
Scientific references:
Please visit https://airsonett.eu/clinical-evidence/for an overview of the clinical documentation of Airsonett Air4 and the TLA-technology.
